NeoStem is initiating a Phase 3 study of Melapuldencel-T later this year under a Special Protocol Assessment agreement with the U.S. Food and Drug Administration, and the therapy has been granted fast-track designation by the agency as well
"Did anyone at ACRX ever do any research into the real world of post operative patient care? It appears not."
Yup, you're absolutely correct, Pentech! Millions spent on developing their product, but not one thought given to the "real world" of post operative care! WHAT were they thinking? You're a genius, man ... sheer genius!!!
NeoStem presents five-year survival data for autologous melanoma Immunotherapy
NeoStem announced results of a pooled analysis indicating that Melapuldencel-T, an investigational patient-specific immunotherapy for metastatic melanoma, may increase survival rates significantly for patients at the most advanced stages of the disease. The findings will be presented on Sunday, June 1 in a poster by Robert O. Dillman, MD, study author and Vice-President, NeoStem Oncology, at the 50th Annual Meeting of the American Society of Clinical Oncology, or ASCO. The analysis to be presented at ASCO includes a subset of pooled data from three melanoma clinical trials, conducted successively from 1990-2011. Two of these trials, one of which was controlled and one of which was not, studied Melapuldencel-T. The new pooled analysis indicates significantly better five-year overall survival rates in patients treated with Melapuldencel-T than those treated with the comparator therapy for the subset of patients who still had evidence of disease after prior treatment with one or more standard therapies. "This subset analysis lends further support to the view that tumor-initiating cells are viable targets for therapeutic interventions like Melapuldencel-T, aiming for better overall survival, even for patients in the most advanced stages of malignant melanoma. In addition, the product may have significant safety and tolerability advantages over existing therapies," said Dr. Dillman. Chief Medical Officer Douglas Losordo, said, "NeoStem is excited to continue investigating this promising therapy in a large-scale Phase 3 study beginning this year." Melapuldencel-T was developed by California Stem Cell, Inc., which was acquired by NeoStem in May. NeoStem is initiating a Phase 3 study of Melapuldencel-T later this year under a Special Protocol Assessment agreement with the U.S. Food and Drug Administration, and the therapy has been granted fast-track designation by the agency as well.
It's really ALL speculation, but the cynic in me tells me it is manipulation, albeit a lot of money spent to create the illusion of "profit-taking" from our recent run up. In the face of positive news and no real market sell-off, I saw it as a means to accumulate some shares all day (like we are seeing) at a lower price. It's all good because once the accumulation ends, we go higher based on improving fundamentals.
The REAL trick, bnytch, is to KNOW what you own so that you don't get shaken out by those kinds of moves. The most blatant move was when they took it below $5. If it doesn't make sense when that happens, just take a deep breath and add to your position, even if those shares are simply a trade.
Good luck ... being confident in where you are and letting the story play out is the key.
Wouldn't you love to know "who" felt the need to dump 80,000+ shares at the open this a.m. on the heels of an upgrade and announcement of a new client? Um hmmmmmm ....
Got that alert this a.m., too, G ... In fact, I added on the orchestrated take-down after the open, too, based on a new customer and the "speculative buy" issued this a.m. This is soooo under the radar!!!
Pentech has been making that same "little blue pill" argument for months! Maybe he's thinking of that "other" little blue pill that ends up on the floor and he can't figure out why "things" aren't working?
Not on the boards much ... Lightened up on ACRX awhile back, but still hold a fair position.
Busy being the general contractor for a total remodel on my daughter's home and helping my sister. Thanks so much for asking...not good! Life sure can throw you a curve ...
I'm more than comfortable with my position here. Got in early and will let it play out!! Thanks for the concern, though!
Lots of things lining up here ... accumulate and/or buy the dips!!
SEC would not have sided with UNIS if there was one WHIFF of impropriety!! Game, set, match, shorts! Just cover and go long? There are only pennies to be made from this point!
7:31 am Neostem announces grant of two U.S. patents for CD34 cell program (NBS) :
•Co announced the expansion of intellectual property protection surrounding its CD34 Cell Program. That program is developing therapeutics to address ischemia, the process that occurs when the supply of oxygenated blood in the body is restricted.
•The recently granted U.S. patents relate to AMR-001, the Company's most clinically advanced product candidate in its CD34 Cell Program, which is designed to treat damaged heart muscle following acute myocardial infarction
Thanks for your service, G. And, yes, Memorial Day is for those who sacrificed everything. People should know it is more than just a long weekend for a picnic or yardwork.
Have a nice day trigger.
I've never hidden the fact that I take profits when I can on extra shares, but hold a decent core. Under $9 was a good point to accumulate some. So, what's your strategy here, if you don't mind sharing?
No worries ... In under $4 for most of my shares and lightened up well over $10. Back in accumulation mode as risk/reward continues to improve. Always keep $$ for exaggerated moves ... buy the dips, sell the rips works sometimes, but being early and waiting for the story to play out is good, too. Just depends on one's philosophy. After many years in bio-techs, you learn to take profits when you have them and live to fight another day.